“Jean brings unprecedented experience, passion, and drive to deliver new innovative treatments to patients suffering from chronic pain disorders and hearing loss. Hoba will benefit hugely from Jean’s expertise and leadership in drug development, financing and corporate development,” says Torsten M. Madsen, CEO of Hoba Therapeutics.

Jean Combalbert

Jean Combalbert PharmD, PhD has over 25 years of experience building research and development-stage biotech companies and achieving high-value exits, describes the company. Jean is currently chairperson at Kynos Therapeutics Ltd, and a non-executive director at Epics Therapeutics SA, having previously served as its founding CEO from 2017. Jean was Chair of the Board at Syndesi Therapeutics SA from 2018 until its sale to AbbVie in 2022. Previously, he was CEO of Ogeda SA from 2006 until its sale to Astellas Pharma Inc. in 2017. Earlier in his career, Dr Combalbert held senior positions with Sanofi and Galderma in France and the United States.

“Hoba is in a unique position to deliver truly transformative therapies for patients with chronic neuropathic pain disorders,” says Jean Combalbert. “Hoba has an exciting pipeline of innovative compounds aimed at the underlying causes of diseases and thereby bring a differentiated approach to treating these diseases. I am excited to join the company and I look forward to working with the highly skilled management team and the Board as Hoba moves into clinical development.”